Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Non-hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)WithdrawnNCT00551239
What this trial is testing

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
LeukemiaLymphoma
CTI BioPharma
Testing effectiveness (Phase 2)Study completedNCT01153971
What this trial is testing

Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 47
Testing effectiveness (Phase 2)Study completedNCT00493467
What this trial is testing

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 31
Large-scale testing (Phase 3)Study completedNCT01609010
What this trial is testing

MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 313
Testing effectiveness (Phase 2)Study completedNCT00509379
What this trial is testing

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Who this might be right for
LymphomaNon-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 48
Testing effectiveness (Phase 2)Study completedNCT00005579
What this trial is testing

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
University of Vermont
Not applicableStudy completedNCT00398372
What this trial is testing

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Who this might be right for
Lymphoma, Non-HodgkinLymphomas: Non-HodgkinLymphomas: Non-Hodgkin Cutaneous Lymphoma+6 more
Stanford University 500
Testing effectiveness (Phase 2)UnknownNCT00258336
What this trial is testing

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Favrille 56
Large-scale testing (Phase 3)WithdrawnNCT02576275
What this trial is testing

Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Who this might be right for
Indolent Non-Hodgkin's LymphomaFollicular LymphomaSmall Lymphocytic Lymphoma+1 more
SecuraBio
Not applicableEnded earlyNCT02273856
What this trial is testing

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)

Who this might be right for
Indolent Non Hodgkin's Lymphoma (iNHL)Chronic Lymphocytic Leukaemia (CLL)
Astellas Pharma International B.V. 25
Not applicableLooking for participantsNCT06822829
What this trial is testing

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)Indolent B-Cell LymphomasIndolent B Cell Lymphoma
Azienda USL Reggio Emilia - IRCCS 50
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Testing effectiveness (Phase 2)Ended earlyNCT00954005
What this trial is testing

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

Who this might be right for
Indolent Lymphoma
German Low Grade Lymphoma Study Group 56
Testing effectiveness (Phase 2)Ended earlyNCT00768339
What this trial is testing

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell
Aegera Therapeutics 25
Testing effectiveness (Phase 2)Ended earlyNCT02898259
What this trial is testing

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Who this might be right for
B Cell LymphomaLymphoma
Brian Hill 19
Early research (Phase 1)Ended earlyNCT04431635
What this trial is testing

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Who this might be right for
Indolent Lymphoma
University of Michigan Rogel Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT02682641
What this trial is testing

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Who this might be right for
Mantle Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 50
Testing effectiveness (Phase 2)Ended earlyNCT00493454
What this trial is testing

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 6
Large-scale testing (Phase 3)Study completedNCT01321541
What this trial is testing

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Who this might be right for
Diffuse Large B-cell Lymphomade Novo DLBCLDLBCL Transformed From Indolent Lymphoma+1 more
CTI BioPharma 312
Next Page